This site is intended for healthcare professionals
Improving patient outcomes in chronic spontaneous urticaria
CSU Learning Zone
Declaration of sponsorship Novartis Pharma AG

Industry-Sponsored eLearning

Declaration of sponsorship Novartis Pharma AG
Read time: 160 mins
Last updated:29th Oct 2021
Published:29th Oct 2021

Put your knowledge of chronic spontaneous urticaria (CSU) to the test.

  • Explore a range of eLearning modules to improve your understanding of CSU
  • Familiarise yourself with the guidelines and learn more about the anti-IgE pathway
  • Consolidate your learning by taking part in our interactive quizzes

These eLearning modules have been developed by EPG Health for Medthority in collaboration with Novartis Pharma AG

This content below was previously accredited from 12/04/21 - 12/04/22, which has now expired. This content continues to be made available for your education, but will no longer count towards your credits.

Understanding the anti-IgE pathway

Test your knowledge on the role of mast cells, understand the anti-IgE pathway and explore how anti-IgE therapies can be used to treat CSU.

Enrol

Closing questions Test your knowledge 5 mins
Introduction Introduction to the eLearning module 5 mins
Section 1 Meet the experts 5 mins
Section 2 Background 5 mins
Section 3 Mast cell activation 10 mins
Section 4 IgE receptors 10 mins
Section 5 IgE inhibitors 10 mins
Section 6 Summary 2 mins

Course overview

On completion of this module participants should have a good understanding of:

  • the role of mast cells and their mediators in CSU pathogenesis
  • the differences between type I and type IIb autoimmunity
  • the differences between the IgE receptors FcεRI and CD23
  • how anti-IgE therapies can be used to treat CSU

Evaluation questions will be asked at the end of the module. You must achieve a score of 60% or above to pass.

Faculty

Marcus Maurer.pngProfessor Marcus Maurer. Professor of Dermatology and Allergy at the Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany. He is also the Director of Research at the Department of Dermatology and Allergy, Associate Director of the Allergie-Centrum-Charité, and Head of the Specialty Clinics for angioedema, hereditary angioedema, urticaria, mastocytosis, pruritus, auto-inflammatory disorders, and the Dermatological Allergology Laboratory.

Dr. Alexander Eggel.pngDr Alexander Eggel. Principal investigator at the Department of Rheumatology, Immunology and Allergy at the University of Bern, Switzlerland. His major research interests include the biological mechanisms underlying both beneficial and pathologic type 2 immune responses.

Benefits of IgE inhibition in patients with CSU

Explore how the IgE pathway has emerged as an important therapeutic target in CSU and discover the benefits of current and future anti-IgE therapies in this interactive module.

Enrol

Closing questions Test your knowledge 5 mins
Introduction Introduction to the eLearning module 5 mins
Section 1 Meet the experts 2 mins
Section 2 The burden of CSU 5 mins
Section 3 Management of CSU 5 mins
Section 4 Unmet needs in CSU 10 mins
Section 5 Anti-IgE therapy 5 mins
Section 6 The benefits of current and future anti IgEs 10 mins
Section 7 Summary 2 mins

Course overview

On completion of this module participants should have a good understanding of:

  • the humanistic and economic burden of CSU
  • current EACCI/GA2LEN/EDF/WAO guidelines for the management of CSU
  • the limitations of currently available therapies
  • the benefits of current and future anti-IgE therapies

Evaluation questions will be asked at the end of the module. You must achieve a score of 60% or above to pass.

Faculty

Marcus Maurer.pngProfessor Marcus Maurer. Professor of Dermatology and Allergy at the Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany. He is also the Director of Research at the Department of Dermatology and Allergy, Associate Director of the Allergie-Centrum-Charité, and Head of the Specialty Clinics for angioedema, hereditary angioedema, urticaria, mastocytosis, pruritus, auto-inflammatory disorders, and the Dermatological Allergology Laboratory.

The AWARE study

Put your knowledge of the AWARE study to the test with our interactive eLearning module, which includes insights from urticaria expert, Professor Ana Giménez-Arnau.

Enrol

Assessment Closing questions and results 5 mins
Introduction Introduction to the eLearning course 2 mins
Section 1 About the EAACI/GA2LEN/EDF/WAO guideline 3 mins
Section 2 AWARE study background 3 mins
Section 3 Learnings from baseline data 2 mins
Section 4 AWARE 2-year data 5 mins

Course overview

A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation (the AWARE study) offers insight into the disease burden, and real-world treatment patterns in patients with H1-antihistamine refractory chronic urticaria, under conditions of daily living.

Our interactive eLearning distils the key findings from the AWARE study with expert input provided by Professor Ana Giménez-Arnau from her presentation at the Novartis company-sponsored virtual symposium 'Redefining patient care in chronic spontaneous urticaria' at EADV 2020.

Evaluation questions will be asked at the end of the module to test your knowledge and consolidate learning.

On completion of this course, participants will understand:

  • The aims and objectives of the AWARE study
  • How real-world treatment patterns measure up against the treatment algorithm recommended in international guidelines
  • The burden of CSU and impact of angioedema on quality of life
  • Changes in patient-reported outcomes over the two-year study period

Faculty

Ana Gimenez-Arnau.png
Dr Ana Giménez-Arnau. Associate Professor of Dermatology at the Universitat Autònoma and Pompeu Fabra of Barcelona and consultant Physician in Dermatology and Venereology in the Department of Dermatology at the Hospital del Mar.

These eLearning modules have been developed by EPG Health for Medthority. This content has been developed in collaboration with Novartis Pharma AG. EPG Health received funding from Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non- Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country.

Welcome: